Gordon Cook

22.5k total citations · 3 hit papers
383 papers, 11.2k citations indexed

About

Gordon Cook is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Gordon Cook has authored 383 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Hematology, 137 papers in Oncology and 114 papers in Molecular Biology. Recurrent topics in Gordon Cook's work include Multiple Myeloma Research and Treatments (179 papers), Protein Degradation and Inhibitors (76 papers) and Cancer Treatment and Pharmacology (59 papers). Gordon Cook is often cited by papers focused on Multiple Myeloma Research and Treatments (179 papers), Protein Degradation and Inhibitors (76 papers) and Cancer Treatment and Pharmacology (59 papers). Gordon Cook collaborates with scholars based in United Kingdom, United States and Germany. Gordon Cook's co-authors include Gareth J. Morgan, Faith E. Davies, Graham Jackson, Roger G. Owen, Mark T. Drayson, Sylvia Feyler, Rachel S. Mulligan, S. Sherlock, Walter M. Gregory and Sue Bell and has published in prestigious journals such as Nature, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Gordon Cook

358 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Gordon Cook, Fredrik Schjesvold et al. profile →
Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis

1971 403 citations Gordon Cook et al. profile →
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

2020 330 citations Gordon Cook et al. Blood profile →

Peers

Countries citing papers authored by Gordon Cook

Since Specialization

Citations

This map shows the geographic impact of Gordon Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Cook more than expected).

Fields of papers citing papers by Gordon Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Cook. The network helps show where Gordon Cook may publish in the future.

Co-authorship network of co-authors of Gordon Cook

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Cook. A scholar is included among the top collaborators of Gordon Cook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Cook. Gordon Cook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group 2025 ·British Journal of Haematology ·Sally Moore, (unknown), Christopher Parrish, (unknown), Laura Miller, (unknown), (unknown), (unknown), (unknown), Suzanne Thompson, (unknown), John R Jones, Annabel McMillan, Orla McCourt, Charlotte Pawlyn, Hira Mian, Gordon Cook	0
2	COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network 2025 ·British Journal of Haematology ·Alexandra Smith, Clare Frobisher, Abraham Varghese, Andy C. Rawstron, Simon Crouch, Debra Howell, Adele K. Fielding, Kirstine Eastick, Catherine Cargo, Cathy Burton, Gordon Cook, Nicholas Easom, Reuben Tooze, Patrick Lillie, Eve Roman, Russell Patmore	0
3	Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling 2025 ·Blood ·(unknown), David A. Cairns, Charlotte Pawlyn, (unknown), Eugene B. Ferris, Gordon Cook, Mark T. Drayson, Kevin Boyd, Paula Proszek, Faith E. Davies, Ruth M. de Tute, Matthew Jenner, (unknown), Roger G. Owen, Michael Hubank, Richard S. Houlston, Graham Jackson, Martin Kaiser	0
4	Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry 2024 ·PLoS ONE ·(unknown), Dennis Petrie, Anthony Harris, Laura Fanning, Erica M. Wood, Elizabeth Moore, Cameron Wellard, (unknown), (unknown), Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, (unknown), Zoe McQuilten	0
5	Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial 2024 ·Blood ·Martin Kaiser, Andrew Hall, (unknown), Amy Holroyd, Eugene B. Ferris, (unknown), (unknown), Kristian M. Bowles, Mamta Garg, Anand Lokare, Ruth M. de Tute, Mark T. Drayson, Christina Messiou, Roger G. Owen, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Sarah Brown, Matthew Jenner	0
6	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma 2023 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Amy L. Sherborne, Ruth M. de Tute, (unknown), (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner	54
7	Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic 2023 ·Blood Cancer Journal ·(unknown), (unknown), Graham McIlroy, (unknown), (unknown), Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham Jackson, Gordon Cook	8
8	ANALYSIS OF TECHNOSTRESS EXPERIENCED BY STUDENTS AT THE UNIVERSITY OF CAPE TOWN, DURING THE COVID-19 PANDEMIC 2022 ·Issues in Information Systems ·Gordon Cook, Jean-Paul Van Belle, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
9	Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial 2022 ·Blood ·(unknown), David A. Cairns, Amy Holroyd, (unknown), (unknown), Charlotte Pawlyn, Gordon Cook, Mark T. Drayson, Kevin Boyd, Faith E. Davies, Matthew Jenner, Gareth J. Morgan, Roger G. Owen, Richard S. Houlston, Graham Jackson, Martin Kaiser	21
10	Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response 2022 ·British Journal of Haematology ·Karthik Ramasamy, Ross Sadler, (unknown), (unknown), (unknown), Alison Turner, (unknown), Nathanael S. Gray, (unknown), (unknown), Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark T. Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, M K Javaid	14
11	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk 2022 ·Journal of Clinical Oncology ·Ruth M. de Tute, Charlotte Pawlyn, David A. Cairns, Faith E. Davies, (unknown), Andy C. Rawstron, John R. Jones, Anna Hockaday, (unknown), Gordon Cook, Mark T. Drayson, Matthew Jenner, Martin Kaiser, Walter M. Gregory, Gareth J. Morgan, Graham Jackson, Roger G. Owen	40
12	The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial 2022 ·British Journal of Haematology ·Matthew Jenner, Charlotte Pawlyn, Faith E. Davies, (unknown), Anna Hockaday, Catherine Olivier, John R Jones, Kamaraj Karunanithi, Jindriska Lindsay, Bhuvan Kishore, Gordon Cook, Mark T. Drayson, Martin Kaiser, Roger G. Owen, Walter M. Gregory, David A. Cairns, Gareth J. Morgan, Graham Jackson	11
13	Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche 2021 ·Journal for ImmunoTherapy of Cancer ·(unknown), G Migneco, Gina B. Scott, Jenny Down, (unknown), (unknown), Victoria A. Jennings, Babatunde O. Oyajobi, Karen J. Scott, Emma J. West, Christy Ralph, Adel Samson, Elizabeth J. Ilett, Munitta Muthana, Matt Coffey, Alan Melcher, Christopher Parrish, Gordon Cook, Michelle A. Lawson, Fiona Errington‐Mais	14
14	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort 2021 ·BMJ Open ·Maxine Lamb, Alexandra Smith, Daniel Painter, Eleanor Kane, (unknown), Robert Newton, Debra Howell, Gordon Cook, Ruth de Tute, Andy C. Rawstron, Russell Patmore, Eve Roman	6
15	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2 2021 ·Repository@Hull (Worktribe) (University of Hull) ·Jill Corre, Michèle Sabbah, Fredrik Schjesvold, Amer M. Zeidan, Francesco Buccisano, David A. Sallman, M. Mazzucato, Leigh A. Madden, Maurizio Martini, Eric van Breda, Riccardo Dolcetti, Alessandro Busca, Gordon Cook, Francesco Onida, Annibale Versari, Jean‐Jacques Kiladjian, Roland B. Walter, Laurent Garderet, Marie Robin, Alberto Signore	1
16	Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial 2017 ·Blood ·Charlotte Pawlyn, Martin Kaiser, David A. Cairns, Alina Striha, John R Jones, Vallari Shah, Matthew Jenner, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gordon Cook, Graham Jackson, Gareth J. Morgan, Faith E. Davies	2
17	Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial 2017 ·Blood ·Amy L. Sherborne, Vallari Shah, Sidra Ellis, Farzana Begum, (unknown), David C. Johnson, Roger G. Owen, Mark T. Drayson, Louise Flanagan, (unknown), Walter M. Gregory, Graham Jackson, Guy Pratt, Gordon Cook, Samantha Hinsley, Julia Brown, Matthew Jenner, Martin Kaiser	2
18	Mary Darwin's illness 1996 ·Notes and Records the Royal Society Journal of the History of Science ·Gordon Cook	2
19	Increased glycine absorption rate associated with acute bacterial infections in man 1973 ·British Journal Of Nutrition ·Gordon Cook	12
20	The Liver after Kwashiorkor 1967 ·BMJ ·Gordon Cook, M. S. R. Hutt	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact